lobbying_activities: 1921661
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1921661 | ac60a372-51fa-4eba-a3d0-7047c3f3f378 | Q4 | FOLEY & LARDNER LLP | 15042 | ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY | 2016 | fourth_quarter | PHA | FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market; Issues relating to the Comprehensive Addiction and Recovery Act of 2016. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2017-01-19T11:21:33-05:00 |